Compare LGND & VRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGND | VRNS |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.9B |
| IPO Year | 1992 | 2014 |
| Metric | LGND | VRNS |
|---|---|---|
| Price | $205.70 | $34.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 20 |
| Target Price | ★ $243.50 | $57.55 |
| AVG Volume (30 Days) | 210.9K | ★ 1.7M |
| Earning Date | 02-26-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.76 | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | $251,233,000.00 | ★ $608,677,000.00 |
| Revenue This Year | $47.71 | $14.57 |
| Revenue Next Year | $9.77 | $15.80 |
| P/E Ratio | $80.11 | ★ N/A |
| Revenue Growth | ★ 64.83 | 11.37 |
| 52 Week Low | $93.58 | $30.02 |
| 52 Week High | $212.49 | $63.90 |
| Indicator | LGND | VRNS |
|---|---|---|
| Relative Strength Index (RSI) | 59.66 | 52.87 |
| Support Level | $188.13 | $32.14 |
| Resistance Level | $199.35 | $35.89 |
| Average True Range (ATR) | 9.00 | 1.41 |
| MACD | 0.55 | 0.04 |
| Stochastic Oscillator | 87.20 | 64.76 |
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.